{{distinguish|methimazole|metamizole|acetazolamide}}

{{Underlinked|date=October 2015}}

{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 462249727
| IUPAC_name = ''N''-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3''H'')-ylidene]acetamide
| image = Methazolamide.svg
| width = 220
| image2 = Methazolamide molecule ball.png
| alt2 = Ball-and-stick model of the methazolamide molecule

<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|monograph|methazolamide}}
| MedlinePlus = a601233
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = Rx-only
| legal_status =
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound = ~55%
| metabolism =
| elimination_half-life = ~14 hours
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 6828
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 554-57-4
| ATC_prefix = S01
| ATC_suffix = EC05
| ATC_supplemental =  
| PubChem = 4100
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00703
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3958
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = W733B0S9SD
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00655
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 19

<!--Chemical data-->
| C=5 | H=8 | N=4 | O=3 | S=2
| molecular_weight = 236.274 g/mol
| smiles = O=S(=O)(C\1=N\N(C(=N/C(=O)C)/S/1)C)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)/b7-4-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FLOSMHQXBMRNHR-DAXSKMNVSA-N
| synonyms = ''N''-(3-Methyl-5-sulfamoyl-3''H''-1,3,4-thiadiazol-2-ylidene) ethanamide
}}

'''Methazolamide''' (trade name '''Neptazane''') is a potent [[carbonic anhydrase inhibitor]]. It is indicated in the treatment of increased [[intraocular pressure]] (IOP) in chronic open-angle [[glaucoma]] and secondary glaucoma. Also it is used preoperatively in acute angle-closure (narrow-angle) glaucoma where lowering the IOP is desired before [[Glaucoma surgery|surgery]].

== References ==
* {{cite journal | vauthors = Iyer G, Bellantone R, Taft D | title = In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics. | journal = J Pharmacokinet Biopharm | volume = 27 | issue = 1 | pages = 45&ndash;66 | year = 1999 | pmid = 10533697 | doi = 10.1023/A:1020630712388}}
* {{cite web | author = RxList | url = http://www.rxlist.com/cgi/generic2/methaz.htm | title = Neptazane | accessdate = August 20, 2006}}
* {{cite journal | vauthors = Shirato S, Kagaya F, Suzuki Y, Joukou S | title = [[Stevensâ€“Johnson syndrome]] induced by methazolamide treatment. | journal = Arch Ophthalmol | volume = 115 | issue = 4 | pages = 550&ndash;3 | year = 1997 | pmid = 9109770 | doi=10.1001/archopht.1997.01100150552021}}
* {{cite journal | vauthors = Skorobohach B, Ward D, Hendrix D | title = Effects of oral administration of methazolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs. | journal = Am J Vet Res | volume = 64 | issue = 2 | pages = 183&ndash;7 | year = 2003 | pmid = 12602587 | doi = 10.2460/ajvr.2003.64.183}}

{{Antiglaucoma preparations and miotics}}

[[Category:Acetamides]]
[[Category:Carbonic anhydrase inhibitors]]
[[Category:Sulfonamides]]
[[Category:Thiadiazoles]]

{{antihypertensive-stub}}